Does the Lung Cancer Field Need Another Third-Generation EGFR Tyrosine Kinase Inhibitor?

Fen Wang; Alex A. Adjei

doi:10.1016/j.jtho.2020.02.021

Does the Lung Cancer Field Need Another Third-Generation EGFR Tyrosine Kinase Inhibitor?

Fen Wang, Alex A. Adjei

Medical Oncology

Research output: Contribution to journal › Editorial › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	881-883
Number of pages	3
Journal	Journal of Thoracic Oncology
Volume	15
Issue number	6
DOIs	https://doi.org/10.1016/j.jtho.2020.02.021
State	Published - Jun 2020

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine

Access to Document

10.1016/j.jtho.2020.02.021

Cite this

@article{c6eebdb20a2344fa87f480076eb01ad1,

title = "Does the Lung Cancer Field Need Another Third-Generation EGFR Tyrosine Kinase Inhibitor?",

author = "Fen Wang and Adjei, {Alex A.}",

year = "2020",

month = jun,

doi = "10.1016/j.jtho.2020.02.021",

language = "English (US)",

volume = "15",

pages = "881--883",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",